TMLHE

trimethyllysine hydroxylase, epsilon

Basic information

Region (hg38): X:155489011-155719098

Links

ENSG00000185973NCBI:55217OMIM:300777HGNC:18308Uniprot:Q9NVH6AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • epsilon-trimethyllysine hydroxylase deficiency (Limited), mode of inheritance: Unknown
  • autism spectrum disorder (Disputed Evidence), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Epsilon-trimethyllysine hydroxylase deficiencyADBiochemicalThe condition may be associated with autism, and carnitine supplementation has been reported as beneficial related to developmental milestonesBiochemical; Neurologic21865298; 22566635; 25943046

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TMLHE gene.

  • Epsilon-trimethyllysine hydroxylase deficiency (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TMLHE gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
6
clinvar
1
clinvar
8
missense
23
clinvar
4
clinvar
27
nonsense
5
clinvar
5
start loss
0
frameshift
1
clinvar
1
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
0
Total 1 0 29 10 1

Variants in TMLHE

This is a list of pathogenic ClinVar variants found in the TMLHE region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-155491566-T-C not specified Uncertain significance (Jun 03, 2022)2293621
X-155491606-G-A Uncertain significance (Oct 22, 2020)1317993
X-155491623-C-T not specified Uncertain significance (Feb 06, 2023)2480649
X-155491644-C-T not specified Uncertain significance (Mar 18, 2024)3327262
X-155492384-C-A Epsilon-trimethyllysine hydroxylase deficiency • not specified Uncertain significance (May 04, 2022)225230
X-155504770-AAACTGGAAAGAGTCCAGATGTGTATTCATAAAAGAAGAGATAAACAGAACAGGCAAAAATCTAATCTATAGTGGTAAAAGAAAATCAAACTGTGGGTTCCTCTGAGATGTATGTGCAGAAGTATGAGAGTACTTCCTGTAGTGATAGTAATATTTTATATCTTGATAAGGGTTTGGGTTAAATAGGTATATGCATTGGTCAAAACTCAGTGAGTGTATATTTAATATTTTAAACATCATTGCATATACATTGTAACTTTAAAAAGCTGTAAGCAAATATTGAACTCTACTTAATGATATAAATGTTGAAGTATTAGGGAGATATGTACTGATATCTGCAATGTATTATACTTTAAAATTCACTGAAAATAAGATTAACTGATGAATGAATAGATGGGAAGATAGGTGATAAAGCAAGTATAGAAATATCTTAATGGTAGAATCTAGATGTAAGTCTATGGCTTTTCTGTGTTAAATGTTTTCAACTTTTCTATATGTTTAGAAATGTTCATAATAAAATGTTGGGAAAATAGAGTTACTACTCATTGTTTTAGGCACTTAGATATATGAGAGATAACAGAGGGAGAGTTTCCCAGAGGAACTTATCCAAGGGAAGTAAATTAATATTTACACAGTTCCTCCTACAAGCCAGGGGTAAAGGTAAGGATAACAATTTATTTTTAACTTCACAACAAGTGGGCACAGAAGGTATTATTATTGTAACTGGAAACTCATGACTAGCAGGTTAAGTAACTTGTCCAAGGCCAAAAATCAATAAATGGCAGACAGGATTTCACACTGAACTCCTTCTGATTACAAAGCCTGTACTCTTTGTAGTATGTCAAGTTTTGCAGCTATCTTCACCCTGCCTCTTCACCCCATATCTCCTTCCCTGCTTTTTTGTTTTTCCCTAGTACTTATCACAATTTGATATATTATATATTTGCTTATTTATTTTTAATTACTCTGTCGTCACTATAATGAGAATTCCAAGATGGCCAGGAATTTTTGTCTATTGTGCCTACAGTTTCATCTGCAGTGTCAAGAACAGAGCATGACTCTTGGTAGATGCTCATGAAATATTTGCTGAGTAAACTGAATTAATGCACAGTAACAGTTTGCTTGGAATAAGCAGAAGCAGGAGCGGTAATCCATCTGCAAAAATGCATAGTAAAAAGCTTGGCTGCAAGATGCAAAATAATGGGCTCCAGAAACCCAAAGCAGTTTGGAATAGCTAGGGAAGAATGTATGGAAAACATGAATTACATGCTAGAAGAGTAAGAAGGGATCAGATCATACAGAACCTTAAAAGCCATAAGGAAGGACTCTAGTCTTTCTCTGAAAGACACTGGGGAGGTTTAGAAGGATCTTAACATGGGAGCAGAAGATAAGACTCAGCATGAAAAATTAATGGAAGAGGGCTCACAATGGAAGCAAGGACATCAGTTACAACTTTAGCCATGGGAAAGAAAAGTGTTCTCACTGCAAGAAGAGGCATTGTAGATAGAAAGCAGGGGATAGTTTGAGAAAAATATAGGAGATTGAGTTGATAAGACTGGTTGTGTAATATAAGGGAGAGGGAAAAATTAAATATGATGTTTGGTTTATGGCTTGGGAAACTTAGTGGATGGTGGTACCATTCAATGAAAATGGGAAAACAAGTGGAGAAGTAGGTTTAAAATGAGTAGAAGTGATGAGTTCACGTTTGAATATGATATGTTTTATATTCTACAAAATATCTAAGTTGTGATATCAGTAGTCAATTGAATACACAGGTCAAGAGCTTTGCATAAATCTGGGCTGGATACATAAATGTTGTTGGGTAACCTAGCTGTTTGGTCACTGAGGATAATTTAATAACTCTTTTTCATTTAATAATGTTTTCATTTAAAAAATACTACCTCTAATATTTGACCCCACCCCTAAAATAAACCTAGTATTCTTTGGTTGGTGGCTATTTACTATTCCATGGGAATTATAAGAAGAATACAAACTGTTTGATAATAAAAAGCTATAGAATAGCAAGATTAAAATGTAGCAGATATAAGAATCTTAGGGATTTTTGTTACATTAGAAGGCTAATCTTTGGCAAATATATTACAGTTGGGGATAGTTCTTTGATACTCACCTGATCAAATACAGCTCTTTATTCCATGGGTAGATATTTAAGACTGGCCCAATCCCAATCATGTGGTTGTGACATTCTCCAACATCTTCAATATATTCATGCTTCAATGGCACTTTACTGAGGAGTTCAAATTCCTCAGGTGCCTTTTGAAGTACCTGTTCTGCTGCATAGAATCCATCTACTAGCAGTGTCCTGCCACCAGTTCCTTCATGTTTAAGACAATGAAACACTTGAATGCTAAAGAGAGAAAAGAAAATTCTTCTGTTCAGTGGAAGAGAGAACATATCAAAATTCTAGAAATTATATATAAAATGATTACTGAAACTACTTGTCATTTTCTTTTCATTTCCTAATTGGAAATCTCATTTCTTAATTGTTTTTCTCTCATAGGCAGTTGTACTTTTTTGTGTTTTGAAATATTAATGCCACTAGAGGTTTCTTCTAAACATATCTAACATATATTGAAGCTTATATGTGCTGGGCCCTGGGAATACAGGCATGAATAATATATAACCTATATTTTCAAGAAGCTCATAGTCTAGTAAGAAGAACTAAAGCAAATAAATACCAAATAAAATATGATAGGTACTATAATAAAGTTGCATACAAGATATAGTGGGGTCATAAACAAAGGAATGATCTGTTCTAGCGGGGTGTTGTATAAAGAAATGTTTTGGAGAAGAATGAAAATTGTTTTGACTAATCTTAAAGAATGAGCAAGAATTGGAGTAGAAGGAGATTGAGATGAGGAGAAGGCATTCTAGGCGGAGAGAAAGCATGACCAAAGATACCAATGTAAAACAACAAGGAGTAAGAAGTTCCTATTGGCATAGCACAGAGAACCACAAAATGATTTTAAACTGTGAAACTCTACGGCCATATCAATATTTTAAAGAGTCCATTATGTTGATAGTGTGGAACATGGACTGGTGAGAAGCAACGTGACAAAAAACTTGGAAACCAACTTGAACAACTGAAATAGTAAAGAAAAATATTGAGAGCTTGAACTCAGAAAGGGGCGTTATAGAGAAGAAGACACACCTGAGAGATACCGAGATAGAAGTAGCAGAATTTGATAACTGAAGGATAGGCAAGAATCTAGAATAACTCCAGGTTTCTCACTTGGGCACCTGAAAAATGATAATGCTATTTACTAAGACCGAGATTACAGACAGATATGCTGTTGAATGATAATGAGGAAGTATGAGAGGTTGAGGAAGGAGTTCAGTTTAGAGGCATGTTAGAACAGCTAATCATATACAGTTTCTGAATATGTTAACAGGGAAAGGTAAGGTGACTATTAATTGACTGGAAAACTAAGGTAGAATTTTCAAACTTATGAGGGAAAATAAAATTAATAGTAATTTAATCAAATATGCAAAACTAAGAAAAAGTAAAAAGCAAATTAAAATAAGAAATAAACAAAAATATGGAGTAAAATCAAGGACAATCTAATATAATATAAATACAATTAAAAAGAGAAAGGTAAGCCTGGCCATATTGAAATTTCTGTGAAACTTCTAGGTCAGGGTTATTTAGTTACCAGTTAAAGATGTTTAAGGAAGAGAGGTGGATTTTGTTACAAGTGATAGCTAAAGCCAAGAGCATGGAAGAGGTCGTTTGGAGAGATCATTTCAAGTAAGAAAAGAGGGATAAGGAGAAAACCTTGAGGAAGAATAATATTTAGGAAATAGACAAAAGAAGCCAGCAAAGGAGGCTGAGGAAAAATGGTCAGATATATAGGAAGAAAACTAGGAAAGAAGGAATATTTAAGAAATTTAGTAGTGGTTAATGGTATGTCTCAGGGATCAAGTAAGATGACAGTACACACTGGATATGACAATTAGTTGCTGGTGACGTTAGAGAGAGTAACTTTAATTGCGGTGAGGGGTGGGTTGGGAAAACTAGATGCCTATGGGTTTGAGGAGTAAATGGGAAGTGAGAATGAAAATATATTGAATGTAGCTATTATTCTTTTAATAATCTTAGCCATGAAGTGGAAGAAAAAAACATGGCTGTAGCTAAACGGAGATAGAGTCCAAGGAAGTACAAAAATAGAGAATTAAGATATGGGAGGCTGATAAGAAGGAGTCAATAGGTATGGAAAGGCTGAAGATAGAGGAGAGAGAAATCCCCAAGGAAGCTGGAAAGGATGAGATCCAGAGCAAAGATAGCTTTAGAGAGAGTAAAGCATATAACAATGAAGATAGTGATTAAAATGAATAAAATGATGAAAATTATAGCTAATATTTATTGAACACTTAGTTTGTGTCAGGCAGTATGATCATATAATTTAATTCCTTAGCAATGCTAATGGATAGGTTAGTTTGTGTCAGGCAATATGATCATATAATTTAATTCCTTAGCAATGCTAATGGATAGGTTTTATATTACTAGTCCCATTTTACAGATGAGGAAACTGAAGTACAGAGAAATTAAGTTACTTGTCCAAGATCACAAATCTAATACATGTTGAGGCTGGAATGCAAATCTGGGTCTGGTTGATGCCATAGCCTGAACTCTTAAGTGCTATTACCATACTGCTAATTTACTTGGTCCTTGCCATTGATTACAAACAATTAAACTAAAGCCACAAACAGTTGTTTATCTCTGGTGTTGGTCATAAAGGGAAGAGCTAGTCAGTATTTGAACCTCAACCCCTGTACAGCTGCTTCTTATCTCATTTCCTCTTTTTTCCTTCTGTATCCACTAGAATGAGGATGCAGGGTTGTTGATCTCTCCATATATTGATAACATTTATCAGGATATCTAAAAGCTGCTTTGTTCTTCCTTCCCTGAATCAAACATTCTTAAGTTATAAACCCTTAAAGGAAATCAGTGTAACCATGAGCAATTGCATATTATCATCCTCTCATATAGTCTCCATAAATCTATGTGCACTCATTTTACTCATATCTTTGTGTCTCAGGCTCACCATCTAAATGCAGAAGCAAGATCAAGAACACGGAATAACCACAGAGGTGCCTCTACTGAAGAGCAAATGGTAGGAAAATTGAGTATAGTATGTATCATCTTTGGTTCAAAAGCATCTTATTCCGTGTGAAGAAGTTATTCTTCCATCATTCCTCCTCTCCAACTTCTTGTAAATCAGATTCAAATTCTTCTTAATGCCATACTCAAAGCAGCTGTGTTTGCATGACGACCCTTTTGCAATATGTTAATAACTAAATGCAAGAAATCTGTACAAATTCCAAAACTAATGGTTAGGCAATACTTTTTTGGGGGATAATTTATAATTACTTTGAAAAATGTAAAATTACATTTTAATAATTAACAAAATTAGGACTCCATTTATATAGTAAGATGAGTTTTCTTTTTATTTTATTTTATTTTATTTTATTTTATTATACTTTAAGTTTTAGGGTACATGTGCACAATGTGCAGGTTTGTTACATATGTATACATGTGCCATGCTGGTGTGCTGCACCCACTAACTCATCATCTAGCATTAGGTATATCTCCCGATGCTATCCCTCCCCCCTCCCCCCACCCCACAACAGTCCCCAGAGTGTGATGTTCCCCTTCCTGTGTCCATGTGTTCTCATTGTTCAATTCCCACCTATGAGTGAGAACATGCGGTGTTTGGTTTGTTGTTCTTGTGATAGTTTGCTGAGAATGATGGTTTCCAGCTCCATCCATGTCCCTACAAAGGACATGAACTCATCATTTTTTATGGCTGCATAGTATTCCATGGTGTATATGTGCCACATTTTCTTTATCCAGTCTATCGTTGTTGGACATTTGGGTTGGTTCCAAGTCTTTGCTATTGTGAATAGTGCCACAGTAAACATACGTGTGCATGTGTCTTTATAGCAGCATGATTTATAATCCTTTGGGTATATACCCAGTAATGGGATGGCTGGGTCAAATGGTATTTCTAGTTCTAGATCCCTGAGGAATCGCCACACTGACTTCCACAATGGTTGAACTAGTTTACAGTCCCACCAACAGTGTAAAAGTGTTCCTATTTCTTCACATCCTCTCCAGCACCTGTTGTTTCCTGACTTTTTAATGATTGCCATTCTAACTGGTGTGAGATGGTATCTCATTGTGGTTTTGATTTGCATTTCTCTGATGGCCAGTAATGATGAGCATTTTCTCATGTGTTTTTTGGCTGCATAAATGTCTTCTTTTGAGAACTTAAAAATATTTTATTCCTAGGAGTCTGATATAGTTTGGATATTTATCCCCACCAAAATCTCATGTTGAATTGTAATCTCCAGTGCTGGAGGTAGGGCCTGGTGGAAGTGTTTAGCTCATGGAGGTGGATAACTGATGGCTTGGTGCTGTCTTCAGATAGTGAGTGAGTTCCTGTGACAGCTAGCTGTTTAAAAGTGTGTGGCACCTCCTCCCTGACTCTCTCTCACTTGCTCCTGTTTTTGCCATGTGAACTGTTTGCTCCCCGCTCACCTTCCACCATGATTGGAAGCTCCCTGAGGCCTCCCCAGAAGAAGATGCTGCTATGCTTTCTGTATAGCCTGCAGAACCATGAGACAATTAAATCTCTCTTTTTTTTTTTTATAAATTACCCAGTCTCAGGTATTTATTTATAGCAATGCAAGAATGGCCTAATACAGAATCTAAAAACTGAGTTAAGGTATTTCAAAATGATCATGTTTCTAGGGGAAGAGAAAGTCATACAAATCTGCAGGAGCAGATATGATCTTGGTTCGAACAGAATGGAAAATAATTAAGAAACCACTCAAGACTATCACATATAAAGACTTTACACTGTAAAAGTCTAATCCACCTACCCACAGGGCTCTTGAAAATAGGTAGTGTCAGTGTGCCGATCCAGAGCTAGCTTGGTGTACGCAGTGTCACCTCTGGAGAAGTCTGAAGTGAAATACCACATCCTCCCATAAATGGTTTCTCTGTTAGTTGAAATAAAGAAAGACCTGTTAGCTATTTGAAATGTTCATTCTTGTCTTTCAAAACTCCTTCCAATACCTTCTTTAGTTACTCACAAATAACAGTAGATTTTTTTGGTTCCAGAATTTAATCCATAAGGTGAAAATGACAGTTGAACATGCTAGTCTTGACAATTCTGTCACTTATTAACATTCTAGAAAGTTGGGGAGAAAACTGTGGAAGTATAATATTGTATTATGAAAGCTTGGAGAATCATCCCACTCTGATTATGTGCCCAGTTTTCATAGCCTTCATAAATTCAAGGTTCTTTTCTATGCTCACCTTTCTTTCACAGAAAAAGATATAGCTGCTTCTGGAAGTGATTTTTTTATTTTATTTTATTAATTATTATTATACTTTAAGTTTTAGGGTACATGTGCACAATGTGCAGGTTTGTTACATATGTATACATGTGCCATGCTGGTGCGCTGCACCCACTAACTCATCATCTAGCATTAGGTATATCTCCCAATGCTATCCCTCCCCCCTTCCCCCCACCCCACAACAGTCCCCAGAGTGTGATGTTCCCCTTCCTGTGTCCATGTGTTCTCATTGTTCAATTCCCACCTATGAGTGAGAATATGCGGTGTTTGGTTTTTTGTCCTTGCGATAGTTTACTGAGAATGAGGATTTCCAATTTCATCCATGTCCCTACAAAGGACATGAACTCATCATTTTTTATGGCTGCATAGTATTCCATGGTGTATATGTGCCACATTTTCTTAATCCAGTCTATCATTGTTGGACATTTGGGTTGGTTCCAAGTCTAACTTTATTTACTATTTTTATAGCTGTTGTCTTTTATTAGTACCATTTTTTCAATAATGGTGGTCATTTCCTAATATTTTGGATAATCCAATTTGCAAGGATGACTGAAGAGTTCTCATATTATTTATAAGACACAGAAGTGATTAATGTAGATCCTCACTCATCTTTTGGACATGGAGGAATAAAGAAAAGAGAAAAGGATAGTTTGTGTTAGCAAGTATTTAGTGAGACTTGCTGTACCATTGTTGTTGTGTCTCTCCTTGAAGTATACATCATATATTTTGATTTTGTAATTATTTTCCTGTTCGGCTCAAATCTGACTAAAGGTCACTTTAATTCTTTAGCTTTCAAAGTTCATCTTATTTTCTGAACCCTTGAAGTTCAAATAGGAAATGCTCTTCCTTTTGAACTATCATCCCTAAAACTGTCTCAATTTATCACTTACCAGCACAGTTTCTTTCACTTGAAAGTTCTCAAACTGTGATTCAAACTGAATGGCTCACAGATGCTGTTGATTATGCTCTACCAGCACAGGGAAGAAGACCCAGCATACTATCTACTACAAAATGAGCTATATCTGGATCTTATTAAGTAAAAGGAAAGTACTAATTATAATAAAGTAGGTTGACATCACACTTAATACTATAGAAGATCAATCTATATACCACCCAAAAGTGCGTAATGGTAATGAAAAAAACAATGTATTTAGGATTAGGAAACCTGGGCTATTTGAATTCAAGTTCTATTGTTTACTAGTAGAGCACTCCTGGGCAAGACACTTGGTATATTTGAGTGTCAGTGCCTCAGCAGTAAAACGGGGACAAAACACACACTGATCAGGGTTCCTATAATAATTAAAAGAAAATAATGGGTGGGAATGTGCTGGCTGAATGCTATATAGCCTTTTAAGGCAGTGTTATTAACAATCAGTCTCTGAATCAAGCCACAGGAATCACAGAAGGTCAAATTGAACAGATGGGAAAATAGAGGACAGTGGGGGTCGAGGGGGTGTGTGTGTGTGTGTGTGTGTGTAATGGACATGCCTATGGTCACACAACTACTTGATGGTAGAACTCAGACTACTATCCAGTTCTCCTTACAGTCAGTGTTTTTTTCCAGTGTACAATAATACCTGTCACTTGGGATCACTGGGCTAGAAACATATTACCAATGACTCTGCAGTCATCATTATATTTTACACATAAGTGTATTTAGAGATTAGAAATCCAGACCTCAAATAAAGTACTGCAAGTGAGAGTCCCTTATTCATGCTACAAAATATTCTGGATTGAAAACGAGGGTGACC-A Epsilon-trimethyllysine hydroxylase deficiency Uncertain significance (Mar 05, 2021)1342626
X-155506930-G-A TMLHE-related disorder Likely benign (Apr 04, 2019)3051170
X-155506930-GAT-G Epsilon-trimethyllysine hydroxylase deficiency Pathogenic (May 04, 2022)225231
X-155506955-A-G not specified Uncertain significance (Jun 16, 2024)3327264
X-155507053-C-A not specified Uncertain significance (Jan 16, 2024)3179800
X-155507054-T-C not specified Uncertain significance (Dec 11, 2023)3179799
X-155507063-G-A not specified Uncertain significance (Feb 13, 2023)2483007
X-155507095-A-G Likely benign (Mar 01, 2023)749213
X-155507099-G-A Epsilon-trimethyllysine hydroxylase deficiency Uncertain significance (Aug 02, 2017)450888
X-155511701-C-G Epsilon-trimethyllysine hydroxylase deficiency risk factor (Oct 23, 2012)225229
X-155511701-C-T not specified Uncertain significance (Mar 25, 2024)3327263
X-155511709-C-T Likely benign (Oct 01, 2022)2661879
X-155511725-T-A Uncertain significance (Dec 07, 2021)2690241
X-155511727-G-T not specified • TMLHE-related disorder Likely benign (Feb 20, 2017)507632
X-155511733-G-A Uncertain significance (Aug 01, 2021)1299221
X-155511738-G-A Uncertain significance (Oct 17, 2022)2429077
X-155511760-G-A TMLHE-related disorder Uncertain significance (Sep 26, 2023)2630958
X-155511762-G-A Likely benign (Jul 31, 2018)761663
X-155513983-TA-T Epsilon-trimethyllysine hydroxylase deficiency Likely pathogenic (Nov 20, 2018)1299348
X-155513995-C-T not specified Uncertain significance (Jun 16, 2022)2284026

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
TMLHEprotein_codingprotein_codingENST00000334398 7179830
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.00007960.77712570912161257370.000111
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.6371121330.8440.000009872753
Missense in Polyphen3747.9840.77109933
Synonymous-0.3485450.81.060.00000380786
Loss of Function1.13812.30.6528.29e-7250

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004310.000415
Ashkenazi Jewish0.0001340.0000992
East Asian0.000.00
Finnish0.00006270.0000462
European (Non-Finnish)0.00009980.0000703
Middle Eastern0.000.00
South Asian0.0004490.000261
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Converts trimethyllysine (TML) into hydroxytrimethyllysine (HTML) (PubMed:11431483, PubMed:23092983). {ECO:0000269|PubMed:11431483, ECO:0000269|PubMed:23092983}.;
Pathway
Lysine degradation - Homo sapiens (human);Carnitine Synthesis;Branched-chain amino acid catabolism;Metabolism of amino acids and derivatives;Metabolism;Lysine degradation;Lysine metabolism;Carnitine synthesis;L-carnitine biosynthesis (Consensus)

Recessive Scores

pRec
0.113

Intolerance Scores

loftool
0.228
rvis_EVS
-0.14
rvis_percentile_EVS
43.29

Haploinsufficiency Scores

pHI
0.194
hipred
N
hipred_score
0.350
ghis
0.455

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.879

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Tmlhe
Phenotype

Gene ontology

Biological process
carnitine biosynthetic process;oxidation-reduction process
Cellular component
mitochondrion;mitochondrial matrix
Molecular function
iron ion binding;protein binding;oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen;trimethyllysine dioxygenase activity